Regulatory Consulting Costs Adhere To Lifecore Long After Intergel Review
This article was originally published in The Gray Sheet
Executive Summary
Lifecore Biomedical expects to retain regulatory consultants for its Intergel adhesion prevention barrier solution during the first half of its 2002 fiscal year, which began July 1, pending a favorable outcome of FDA's Medical Devices Dispute Resolution Panel meeting on Sept. 6.
You may also be interested in...
Data Deficiencies Derail Lifecore Intergel Liquid Adhesion Barrier PMA
Higher than expected infection rates, pending safety data and lingering questions over clinical efficacy prompted FDA's General and Plastic Surgery Devices Panel to recommend against approval of Lifecore Biomedical's Intergel adhesion prevention barrier solution in a 5-2 vote during a Jan. 12 meeting in Rockville, Maryland.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.